vs
ICU MEDICAL INC（ICUI）与泰利福（TFX）财务数据对比。点击上方公司名可切换其他公司
泰利福净利率更高（177.8% vs -2.9%，领先180.7%）。ICU MEDICAL INC同比增速更快（-14.1% vs -150.5%）。ICU MEDICAL INC自由现金流更多（$36.0M vs $-92.9M）。过去两年泰利福的营收复合增速更高（NaN% vs NaN%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
泰利福（Teleflex）总部位于美国宾夕法尼亚州韦恩，是专业医疗设备供应商，产品广泛应用于重症监护、外科手术等各类诊疗场景。公司年营收达24亿美元，在全球40个国家开展业务，员工总数超15000人。经过数年的收并购与业务剥离，公司于2011年完成业务调整，全面聚焦医疗设备制造领域。
ICUI vs TFX — 直观对比
营收规模更大
ICUI
是对方的-1.3倍
$-401.9M
营收增速更快
ICUI
高出136.4%
-150.5%
净利率更高
TFX
高出180.7%
-2.9%
自由现金流更多
ICUI
多$128.9M
$-92.9M
两年增速更快
TFX
近两年复合增速
-2.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $-401.9M |
| 净利润 | $-15.7M | $-714.3M |
| 毛利率 | 37.5% | — |
| 营业利润率 | 1.0% | — |
| 净利率 | -2.9% | 177.8% |
| 营收同比 | -14.1% | -150.5% |
| 净利润同比 | 34.0% | -422.7% |
| 每股收益（稀释后） | $-0.63 | $-15.85 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUITFX
| Q4 25 | $540.7M | $-401.9M | ||
| Q3 25 | $537.0M | $913.0M | ||
| Q2 25 | $548.9M | $780.9M | ||
| Q1 25 | $604.7M | $700.7M | ||
| Q4 24 | $629.8M | $795.4M | ||
| Q3 24 | $589.1M | $764.4M | ||
| Q2 24 | $596.5M | $749.7M | ||
| Q1 24 | $566.7M | $737.8M |
净利润ICUITFX
| Q4 25 | $-15.7M | $-714.3M | ||
| Q3 25 | $-3.4M | $-408.9M | ||
| Q2 25 | $35.3M | $122.6M | ||
| Q1 25 | $-15.5M | $95.0M | ||
| Q4 24 | $-23.8M | $-136.7M | ||
| Q3 24 | $-33.0M | $111.0M | ||
| Q2 24 | $-21.4M | $80.0M | ||
| Q1 24 | $-39.5M | $15.3M |
毛利率ICUITFX
| Q4 25 | 37.5% | — | ||
| Q3 25 | 37.4% | 49.5% | ||
| Q2 25 | 37.9% | 55.2% | ||
| Q1 25 | 34.7% | 55.6% | ||
| Q4 24 | 36.1% | 55.3% | ||
| Q3 24 | 34.8% | 56.3% | ||
| Q2 24 | 34.8% | 55.6% | ||
| Q1 24 | 32.7% | 56.4% |
营业利润率ICUITFX
| Q4 25 | 1.0% | — | ||
| Q3 25 | 2.6% | -44.8% | ||
| Q2 25 | 1.9% | 19.9% | ||
| Q1 25 | 2.1% | 17.9% | ||
| Q4 24 | 6.0% | -13.9% | ||
| Q3 24 | 1.4% | 19.5% | ||
| Q2 24 | 1.3% | 15.6% | ||
| Q1 24 | -1.9% | -0.6% |
净利率ICUITFX
| Q4 25 | -2.9% | 177.8% | ||
| Q3 25 | -0.6% | -44.8% | ||
| Q2 25 | 6.4% | 15.7% | ||
| Q1 25 | -2.6% | 13.6% | ||
| Q4 24 | -3.8% | -17.2% | ||
| Q3 24 | -5.6% | 14.5% | ||
| Q2 24 | -3.6% | 10.7% | ||
| Q1 24 | -7.0% | 2.1% |
每股收益（稀释后）ICUITFX
| Q4 25 | $-0.63 | $-15.85 | ||
| Q3 25 | $-0.14 | $-9.24 | ||
| Q2 25 | $1.43 | $2.77 | ||
| Q1 25 | $-0.63 | $2.07 | ||
| Q4 24 | $-0.97 | $-2.89 | ||
| Q3 24 | $-1.35 | $2.36 | ||
| Q2 24 | $-0.88 | $1.69 | ||
| Q1 24 | $-1.63 | $0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $378.6M |
| 总债务越低越好 | — | $2.6B |
| 股东权益账面价值 | $2.1B | $3.1B |
| 总资产 | $4.1B | $6.9B |
| 负债/权益比越低杠杆越低 | — | 0.85× |
8季度趋势，按日历期对齐
现金及短期投资ICUITFX
| Q4 25 | — | $378.6M | ||
| Q3 25 | — | $354.0M | ||
| Q2 25 | — | $253.7M | ||
| Q1 25 | — | $284.1M | ||
| Q4 24 | $308.6M | $290.2M | ||
| Q3 24 | $312.5M | $243.2M | ||
| Q2 24 | $302.6M | $238.6M | ||
| Q1 24 | $251.4M | $237.4M |
总债务ICUITFX
| Q4 25 | — | $2.6B | ||
| Q3 25 | — | $2.7B | ||
| Q2 25 | — | $1.9B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ICUITFX
| Q4 25 | $2.1B | $3.1B | ||
| Q3 25 | $2.1B | $3.8B | ||
| Q2 25 | $2.1B | $4.2B | ||
| Q1 25 | $2.0B | $4.1B | ||
| Q4 24 | $2.0B | $4.3B | ||
| Q3 24 | $2.0B | $4.5B | ||
| Q2 24 | $2.0B | $4.6B | ||
| Q1 24 | $2.1B | $4.5B |
总资产ICUITFX
| Q4 25 | $4.1B | $6.9B | ||
| Q3 25 | $4.1B | $7.9B | ||
| Q2 25 | $4.1B | $7.4B | ||
| Q1 25 | $4.2B | $7.2B | ||
| Q4 24 | $4.2B | $7.1B | ||
| Q3 24 | $4.3B | $7.5B | ||
| Q2 24 | $4.3B | $7.4B | ||
| Q1 24 | $4.3B | $7.5B |
负债/权益比ICUITFX
| Q4 25 | — | 0.85× | ||
| Q3 25 | — | 0.70× | ||
| Q2 25 | — | 0.45× | ||
| Q1 25 | — | 0.47× | ||
| Q4 24 | — | 0.39× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $-92.3M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $-92.9M |
| 自由现金流率自由现金流/营收 | 6.6% | 23.1% |
| 资本支出强度资本支出/营收 | 4.6% | -0.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.8M | $1.4M |
8季度趋势，按日历期对齐
经营现金流ICUITFX
| Q4 25 | $60.6M | $-92.3M | ||
| Q3 25 | $56.7M | $107.8M | ||
| Q2 25 | $11.2M | $7.8M | ||
| Q1 25 | $51.3M | $73.3M | ||
| Q4 24 | $40.2M | $202.6M | ||
| Q3 24 | $36.1M | $231.1M | ||
| Q2 24 | $82.0M | $91.7M | ||
| Q1 24 | $45.8M | $112.8M |
自由现金流ICUITFX
| Q4 25 | $36.0M | $-92.9M | ||
| Q3 25 | $27.6M | $77.8M | ||
| Q2 25 | $-8.5M | $-26.8M | ||
| Q1 25 | $36.7M | $43.3M | ||
| Q4 24 | $16.1M | $170.6M | ||
| Q3 24 | $16.2M | $209.9M | ||
| Q2 24 | $62.5M | $56.9M | ||
| Q1 24 | $29.9M | $74.4M |
自由现金流率ICUITFX
| Q4 25 | 6.6% | 23.1% | ||
| Q3 25 | 5.1% | 8.5% | ||
| Q2 25 | -1.5% | -3.4% | ||
| Q1 25 | 6.1% | 6.2% | ||
| Q4 24 | 2.6% | 21.4% | ||
| Q3 24 | 2.7% | 27.5% | ||
| Q2 24 | 10.5% | 7.6% | ||
| Q1 24 | 5.3% | 10.1% |
资本支出强度ICUITFX
| Q4 25 | 4.6% | -0.2% | ||
| Q3 25 | 5.4% | 3.3% | ||
| Q2 25 | 3.6% | 4.4% | ||
| Q1 25 | 2.4% | 4.3% | ||
| Q4 24 | 3.8% | 4.0% | ||
| Q3 24 | 3.4% | 2.8% | ||
| Q2 24 | 3.3% | 4.6% | ||
| Q1 24 | 2.8% | 5.2% |
现金转化率ICUITFX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.32× | 0.06× | ||
| Q1 25 | — | 0.77× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.08× | ||
| Q2 24 | — | 1.15× | ||
| Q1 24 | — | 7.38× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
TFX
暂无分部数据
